Palisade Bio Inc. (NASDAQ:PALI) does about 3.63M shares in volume on a normal day but saw 277025 shares change hands in Friday trading. The company now has a market cap of 3.40M USD. Its current market price is $2.31, marking a decrease of -3.35% compared to the previous close of $2.39. The 52 week high reached by this stock is $76.50 whilst the lowest price level in 52 weeks is $1.74. The script in recent trading has seen the stock touch a high of $2.53 and a low of $2.265.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Palisade Bio Inc. (PALI) has a 20-day trading average at $2.41 and the current price is -96.98% off the 52-week high compared with 32.76% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.60 and its 200-day simple moving average is $11.20. If we look at the stock’s price movements over the week, volatility stands at 7.45%, which increases to 12.59% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 44.79 to suggest the stock is neutral.
2 analysts observing the Palisade Bio Inc. (PALI) stock have set the 12-month price targets for the company’s shares at between $25.00 and $25.00. The consensus objective for the share price is $25.00, suggesting that the stock has a potential upside of 90.76% over the period. The median price target is 90.76% away from the current levels at $25.00.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 1 analysts have rated it as a buy and 1 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The current price level is -4.43%, -12.02%, and -79.67% away from its SMA20, SMA50, and SMA200 respectively, with the PALI price moving above the 50-day SMA on February 17. Its price is -55.58% year-to-date and -95.38% over the past year.
The company’s next earnings report is expected on 05/12/2023, with forecasts estimating quarterly EPS at -$2.43 and -$21.43 for whole year. PALI’s earnings per share are forecast to grow by 85.00% this year and 79.40% over next year.
Its 12-month price target is $25.00. To reach the target analysts have set, the stock logically needs to grow 90.76 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $25.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $25.00.
Outstanding shares total 1.54M with insiders holding 11.22% of the shares and institutional holders owning 10.20% of the company’s common stock. The company has a return on equity of -131.50%. The beta has a value of 1.38. Price to book ratio is 0.18.